best glp-1 agonist companies Receptor Market Size & Analysis, 2026-2033 Glucagon-like Peptide-1 (GLP-1) Agonists Market

The reduction of cardiovascular events is not only related to anti-diabetic properties, but also to pleotropic effects leading to the reduction of the residual cardiovascular risk, that has been defined as the risk of progression of CV events (MACE or HF) that remains after the optimal glycaemic control in T2DM patients, and it seems to be related to meta-inflammation, defined as a low-grade chronic and sterile inflammatory status

It comes as a pre-filled injection pen that you give yourself once a week

10.2174/1573399812666151223093841 [DOI] [PMC free article] [PubMed] [Google Scholar] 230.Borner T, Shaulson ED, Tinsley IC, Stein LM, Horn CC, Hayes MR, et al

Psychiatry 45, 5463

Amy Schroeder Principal Research Scientist | July 9, 2025 Current Landscape Overview Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging drug class that are mostly indicated to improve glycemic control in patients with type 2 diabetes mellitus (T2D) and reduce body weight

Protecting that investment with appropriate treatment duration planning makes the extended course worthwhile for most patients